SLC30A7

Across TCGA pan-cancer cohorts, SLC30A7 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of SLC30A7’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SLC30A7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC30A7 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

BLCA, HNSC, and KIRC are the cancer types where SLC30A7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC30A7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+1.112	<.001	12	view →
HNSC	All	III,IV	+0.921	<.001	12	view →
KIRC	Female	III,IV	+0.895	<.001	12	view →
KIRP	Male	II,III,IV	+0.997	<.001	11	view →
STAD	Female	All	+1.227	<.001	9	view →
LUAD	Male	All	+0.714	<.001	9	view →
LIHC	All	II,III,IV	+0.662	<.001	9	view →
KICH	Female	All	−1.040	<.001	7	view →
BRCA	All	III,IV	+0.821	<.001	6	view →
CHOL	All	All	+1.573	<.001	5	view →
COAD	Male	All	+0.601	<.001	3	view →
PRAD	All	All	+0.501	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

SLC30A7–BLCA

Open the BLCA breakdown →